MAPK8 and cholangiocarcinoma: SP600125, a selective inhibitor of JNK, inhibited the phosphorylation of c-Jun in a dose-dependent manner in QBC939, RBE and HCCC-9810 cells (Figure 1B), indicating that SP600125 can effetely inhibit the activity of JNK in human CCA cells.